SEATTLE — Dr. Aris Thorne, senior regulatory affairs officer at MedCorp Dynamics, stands before a whiteboard that reads “MODIFY THIS? FILL FORM 12B-Ω FIRST” in bold black marker. Behind him, a sleek new defibrillator sits on a cart, waiting to do its job or not, depending on paperwork completion.

“For the first time in human medical device history,” Thorne explains, adjusting his spectacles, “we must document what changes we will make before we actually make them. This is the Predetermined Change Control Plan (PCCP), and without it, your defibrillator can’t save a heart. It just… sits.”

The Food and Drug Administration has officially proposed guidance that requires medical device manufacturers to file a PCCP before submitting any changes to a device. In plain English: you have to write down what modifications you plan to make to your medical device, and describe exactly how those modifications will be validated, before you’re even allowed to make the changes.

“It’s like showing your driver’s license before getting to the DMV,” says Dr. Elena Vasquez, lead investigator at the Center for Regulatory Bureaucracy. “You know you’re going to change your license number, so why can’t you tell us what that number is before you change it?”

The proposed guidance documents outline what information should be included in a PCCP for a marketing submission. This includes detailed descriptions of planned modifications, validation strategies, and risk assessments. The FDA is committed to making its guidance accessible, but the accessibility of getting a device modified has arguably decreased.

The Defibrillator Dilemma

Dr. Marcus Wei, emergency room physician at Seattle Children’s Hospital, holds up a pristine defibrillator. “This device was perfect yesterday. Today, I need to update its firmware to accommodate new arrhythmia detection algorithms. But I can’t just update it. First, I must file Form 12B-Ω. Then I must document that I plan to update it. Then I must describe how I plan to validate the update. Only then may I actually perform the update.”

“The irony is thick enough to spread on toast,” Wei says. “I spent three hours today writing a document predicting that my defibrillator’s firmware would be updated next week. The firmware was updated yesterday. But by the time I finished the document, it was already done. I had to file a PCCP for a change that happened before I planned it.”

This is not an isolated incident. Across the medical device industry, manufacturers are reporting similar frustrations. “We have a pipeline of innovations waiting to hit the market,” says Jennifer Park, director of product development at MediTech Innovations. “But every time we want to improve our pacemaker’s battery efficiency, we’re told to ‘plan the improvement’ before implementing it. By the time we plan it, the innovation is already obsolete.”

The guidance also emphasizes the importance of risk assessment. “We must document all potential risks associated with our planned changes,” says Dr. Wei. “This includes risks of the change not happening, the change happening too soon, the change being too ambitious, and the risk of someone reading our plans before we’ve finished them.”

Regulatory Rationale and Real-World Consequences

The FDA’s rationale for the PCCP guidance is to improve transparency and pre-market review. In theory, this makes sense. In practice, it creates an absurd bureaucratic loop.

“The PCCP is meant to ensure that manufacturers think through their changes before implementation,” explains Dr. Sarah Jenkins, FDA regulatory specialist. “But in reality, it means manufacturers are planning changes that haven’t been conceived yet. It’s like requiring a marriage license before people decide to fall in love.”

The impact on innovation has been swift and severe. “We’re seeing a chilling effect on device development,” says Dr. Wei. “Companies are choosing to stagnate rather than file for planned changes. This means patients get less innovative devices, and more devices that work exactly as they did five years ago.”

Meanwhile, the red tape continues to accumulate. “We’re now filing PCCPs for changes that haven’t happened yet, for changes that will be cancelled before they’re planned, for changes that are already being implemented without plans,” Park says. “The bureaucracy has its own timeline, and it’s not aligned with patient needs.”

Looking Forward

The FDA’s guidance on PCCPs is just the latest in a series of proposed changes that require medical devices to be more bureaucratic. The trend is clear: the regulatory landscape is moving toward a future where every medical device must be filed, planned, and approved before it can do anything.

“If we’re lucky,” says Dr. Vasquez, “we’ll be able to change our devices without filing forms. If we’re not, we’ll be filing PCCPs for the changes we make to our devices that make them more capable. And if we’re very unlucky, we’ll be filing PCCPs for the changes we make to our patients to make them healthier.”

The PCCP guidance is currently in draft form, subject to public comment. As medical device manufacturers grapple with the requirement, patients are left to wait. And wait. And wait.

For those who need to submit a PCCP, the FDA recommends including detailed descriptions of planned modifications, validation strategies, and risk assessments. But for those who just want their defibrillator to work, the message is clear: plan before you act.